Understanding the Modeling Toolkit Behind Model-Informed Drug Development

Model-Informed Drug Development draws on a growing toolkit of quantitative approaches, each suited to different questions across the product lifecycle. Understanding the distinctions between these approaches is a useful starting point for anyone evaluating where to invest modeling resource.

Physiologically-Based Pharmacokinetics (PBPK)

PBPK models describe drug absorption, distribution, metabolism and excretion using physiological compartments that represent organs and tissues. Within MIDD, PBPK is widely applied to first-in-human dose predictions, drug-drug interaction risk, and dose adjustments in special populations such as paediatrics, geriatrics, pregnancy and organ impairment. Because these models are grounded in physiology rather than empirical curve-fitting alone, they support extrapolation to populations or scenarios where clinical data is limited or unavailable, often reducing the need for additional trials. 

Quantitative Systems Pharmacology (QSP)

QSP integrates detailed biological mechanisms with pharmacokinetic and pharmacodynamic processes to simulate the interaction between a drug, its target, and the underlying disease. QSP has become one of the more advanced components of the MIDD toolkit, increasingly used for dose justification, bridging across indications, and simulating clinical trial outcomes ahead of study conduct. Its value lies in connecting mechanistic understanding of disease biology to predicted clinical response, which is particularly relevant where translational uncertainty is high.

How These Approaches Fit Into the Broader Discipline

Pharmacometrics, population PK, PBPK, and QSP are not competing approaches but complementary tools that MIDD teams draw on depending on the development question. Early discovery and translational work may lean on PBPK to inform first-in-human strategy, while QSP becomes increasingly valuable as a program moves toward demonstrating mechanism, informing trial design, or engaging with regulators on dose selection. Many organizations are now working to embed these approaches earlier in development, rather than treating modeling as a downstream or supportive exercise.

The Regulatory Trajectory

Regulatory acceptance of model-informed approaches has advanced steadily. Agencies including the FDA have incorporated PBPK and QSP into review processes to support decisions on dosing, drug-drug interaction risk, pediatric use, and biomarker-based safety assessment, and continue to engage with sponsors on model-based strategies ahead of submission. Harmonization efforts, including the ICH M15 guideline on general principles for MIDD, reflect a broader move toward establishing consistent global expectations for how modeling evidence should be built, documented, and assessed. This shifting regulatory landscape raises a practical question that goes beyond the science: how does a modeling package need to be structured, validated, and communicated to earn regulatory and internal confidence?

Where AI Fits

Artificial intelligence and machine learning are increasingly being layered onto MIDD workflows, from automated parameter estimation to leveraging real-world data where clinical data is sparse. This is not positioned as a replacement for mechanistic modeling, but as a complementary capability that may accelerate certain workflows while raising new questions around transparency, validation, and regulatory acceptance of AI-assisted outputs.

A Field Built on Shared Language

Organizations working in this space span teams running PBPK and QSP models day to day, to those setting strategy for how and when modeling evidence is used in submissions. Understanding the vocabulary and the trajectory of each approach, PBPK, QSP, popPK, MBMA, PBBM, and beyond, is what allows this community to have precise, high-signal conversations rather than starting from first principles each time.
explore agenda

Explore the Agenda

Preview strategy-led case studies on AI-enabled MIDD, pharmacometrics-biostatistics collaboration and ICH M15 in practice, alongside interactive discussions and hands-on workshops across three content-rich days.

View Presentations & Speakers
partner w us

Partner With Us

Position your organization as the go-to solution provider by showcasing your technologies, services and expertise to senior MIDD decision-makers actively evaluating modelling and simulation partners.

Explore Sponsorship Options
join bio experts

Join Biopharma Experts

Connect with pharmacometricians, clinical pharmacologists, QSP scientists and regulatory leaders through case studies, roundtables and structured networking designed for an intimate room, not a crowd. 

Register Now